SCHEMBL22650291

SCHEMBL22650291

O=C(O)C(c1cc(F)ccc1C1CCCO1)N1CCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
GAA P10253 2/20 0.37
ALDH1A1 P00352 2/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A3 Q01959 2/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
KDM4E B2RXH2 2/20 0.35
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
HPGD P15428 1/20 0.34
CFTR P13569 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 3/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21780664 0.97 LMNA (0.37) LMNAGAAALDH1A1SLC6A2SLC6A3
SCHEMBL21780671 0.84 FFAR4 (0.35) LMNAGAAALDH1A1SLC6A2SLC6A3
SCHEMBL23426235 0.84 FFAR4 (0.35) LMNAGAAALDH1A1SLC6A2SLC6A3
SCHEMBL21780658 0.82 LMNA (0.39) LMNAGAAALDH1A1SLC6A2SLC6A3
SCHEMBL21780619 0.80 SSTR5 (0.34) ALDH1A1KMT2A
SCHEMBL21784985 0.76 LSS (0.33) KMT2A
SCHEMBL21767524 0.72 CFTR (0.43) LMNAGAASLC6A3KDM4ECYP1A2
SCHEMBL31071948 0.72 CFTR (0.43) LMNAGAASLC6A3KDM4ECYP1A2
SCHEMBL15063187 0.72 GAA (0.50) LMNAGAAALDH1A1SLC6A2SLC6A3
SCHEMBL19182797 0.70 LMNA (0.45) LMNAGAASLC6A2SLC6A3CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073511-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2022-03-10 US disclosed
US-11021480-B2 Inhibiting (α-V)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-01 US disclosed
US-20200385384-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN SCHRÖDINGER, LLC 2020-12-10 US disclosed
US-20200354359-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073511-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV LMNA 2012/4885GAA 362/4885ALDH1A1 1504/4885
US-20200354359-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV LMNA 2012/4885GAA 362/4885ALDH1A1 1504/4885
US-20200385384-A1 INHIBITING (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV LMNA 2012/4885GAA 362/4885ALDH1A1 1504/4885
US-11021480-B2 Inhibiting (α-V)(β-6) integrin ITGB6, ITGA6, ITGAV LMNA 2251/4885GAA 333/4885ALDH1A1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.